What changed on 15 January 2026
The Thai FDA published its Announcement on Criteria, Procedures and Conditions for Registration of Medical Device Manufacturing Facilities on 15 January 2026, gazetted on 2 March 2026, effective May 2026. The substantive shift is that the FDA now evaluates manufacturing facility licences against three aligned factors: the risk class of devices handled, the technical capabilities and infrastructure of the facility, and the quality and appropriateness of documented SOPs. SOPs must be tailored to the specific activity — assembly, sterilisation, repacking — performed at the site.
Underneath this, the 2019 four-tier risk classification from "Announcement of the Ministry of Public Health Re: Medical Device Classification According to Risk Level, B.E. 2562" remains the governing taxonomy. Class 1 (low risk) on the FDA Positive List: auto-approved on submission through the e-Submission/SKYNET portal as of January 2025. Class 1 not on Positive List or with measurement function: roughly 4 months. Class 2 (notification) and Class 3 (detailed notification): several weeks to several months on a CSDT dossier. Class 4 (licensing): full evaluation, typically the longest.
Where HIFU, RF and microneedling RF actually sit
The default classification for energy-based aesthetic devices in Thailand: HIFU systems run Class 2 (notification with CSDT), depending on intended use claims; monopolar/bipolar RF systems run Class 2 unless they make therapeutic claims that push them to Class 3; RF microneedling combines two technologies and typically classifies at Class 3 because the microneedling component is invasive and the RF component is energy-emitting. Any device claiming treatment of a disease, condition or "medical" tightening crosses Class 3. Any device marketed as aesthetic-only with no therapeutic claim can sometimes hold Class 2 — but Thai FDA reviewers have become stricter on claim language since 2023.
The new May 2026 facility rules add a layer: even when the device is classified at Class 2, the Thai authorised representative's facility must demonstrate technical capability matching the risk class of products handled. A representative handling only Class 1 devices cannot pivot to Class 3 imports without facility-level reassessment.
The Bangkok premium aesthetic market reality
Thailand is the second-largest medical device market in ASEAN at roughly US$7 billion, importing over 80% of its devices. Bangkok premium clinics — Thonglor, Phrom Phong, Sukhumvit corridor — run Korean and Israeli energy devices at a churn rate of 2-3 years per major piece. Distributors who can move a new HIFU or RF microneedling SKU through Class 2/3 registration in under 6 months hold a real advantage; those who cannot watch the device window close.
Practical guidance: foreign manufacturers must appoint a Thai-based Local Authorised Representative (LAR) with an Establishment License. IFUs and labelling must be in Thai for home-use devices; English is acceptable for professional-use. Class 2-4 devices require quality system evidence — ISO 13485 is the de facto standard.